

Romina Gamberale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2241195/publications.pdf>

Version: 2024-02-01

29
papers

436
citations

687363

13
h-index

752698

20
g-index

29
all docs

29
docs citations

29
times ranked

865
citing authors

#	ARTICLE	IF	CITATIONS
1	Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 979-987.	4.2	7
2	Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 12926.	3.3	3
3	In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 598319.	2.8	13
4	Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 813-824.	4.2	6
5	Second generation <sc>BTK</sc> inhibitors impair the anti-fungal response of macrophages and neutrophils. <i>American Journal of Hematology</i> , 2020, 95, E174-E178.	4.1	10
6	The effect of ibrutinib on neutrophil and $\gamma\delta$ T cell functions. <i>Leukemia and Lymphoma</i> , 2020, 61, 2409-2418.	1.3	16
7	Expression and function of cathelicidin hCAP18/LL-37 in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, e465-469.	3.5	3
8	Chronic lymphocytic leukemia cells increase neutrophils survival and promote their differentiation into CD16 ^{high} CD62L ^{dim} immunosuppressive subset. <i>International Journal of Cancer</i> , 2019, 144, 1128-1134.	5.1	15
9	Effect of the BTK inhibitor ibrutinib on macrophage- and $\gamma\delta$ T cell-mediated response against <i>Mycobacterium tuberculosis</i> . <i>Blood Cancer Journal</i> , 2018, 8, 100.	6.2	31
10	Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies. <i>Haematologica</i> , 2018, 103, e458-e461.	3.5	14
11	Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2017, 102, e257-e260.	3.5	9
12	The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 461-473.	4.2	14
13	Revisiting the role of interleukin-8 in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2017, 7, 15714.	3.3	13
14	Neutrophils from chronic lymphocytic leukemia patients exhibit an increased capacity to release extracellular traps (NETs). <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 77-89.	4.2	48
15	Soluble RANKL production by leukemic cells in a case of chronic lymphocytic leukemia with bone destruction. <i>Leukemia and Lymphoma</i> , 2016, 57, 2468-2471.	1.3	6
16	Surface localization of high-mobility group nucleosome-binding protein 2 on leukemic B cells from patients with chronic lymphocytic leukemia is related to secondary autoimmune hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1115-1122.	1.3	5
17	Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. <i>Haematologica</i> , 2015, 100, e140-e142.	3.5	61
18	Sphingosine Kinases (SK): Key Molecules Associated with the Activation, Proliferation and Ibrutinib-Induced Cell Death of Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2015, 126, 1714-1714.	1.4	0

#	ARTICLE	IF	CITATIONS
19	The Expression of Sphingosine-1 Phosphate Receptor-1 in Chronic Lymphocytic Leukemia Cells Is Impaired by Tumor Microenvironmental Signals and Enhanced by Piceatannol and R406. <i>Journal of Immunology</i> , 2014, 193, 3165-3174.	0.8	21
20	CXCL12 is a costimulator for CD4+ T cell activation and proliferation in chronic lymphocytic leukemia patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 113-124.	4.2	17
21	Methylation status regulates lipoprotein lipase expression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1844-1848.	1.3	16
22	The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells. <i>Investigational New Drugs</i> , 2012, 30, 1830-1840.	2.6	26
23	2.8 CXCL12 Is a Costimulator for CD4+ T-Cell Activation and Proliferation in Patients with Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S164.	0.4	0
24	CCR4 expression in a case of cutaneous Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL) and in CLL patients with no skin manifestations. <i>European Journal of Haematology</i> , 2011, 87, 80-86.	2.2	6
25	CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia. <i>Haematologica</i> , 2010, 95, 768-775.	3.5	13
26	Human Monocytes and Monocyte-Like Cells Are Highly Sensitive to Plitidepsin-Induced Cell Death In In Vitro Assays. <i>Blood</i> , 2010, 116, 4942-4942.	1.4	0
27	Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia. <i>Biochemical Pharmacology</i> , 2008, 75, 857-865.	4.4	18
28	Chronic Lymphocytic Leukemia Cells Bind and Present the Erythrocyte Protein Band 3: Possible Role as Initiators of Autoimmune Hemolytic Anemia. <i>Journal of Immunology</i> , 2008, 181, 3674-3683.	0.8	30
29	SHIP-1 protein level and phosphorylation status differs between CLL cells segregated by ZAP-70 expression. <i>British Journal of Haematology</i> , 2007, 140, 071116225528001-???	2.5	15